Skip to main content

Table 3 Application of the proposed method to the determination of the studied drugs in spiked human plasma.

From: Development and validation of a repharsed phase- HPLC method for simultaneous determination of rosiglitazone and glimepiride in combined dosage forms and human plasma

Compound Concentration taken (μg/mL) Concentration found (μg/mL) % Found
Rosiglitazone 0.10 0.1058 105.80
  0.25 0.2398 95.92
  0.50 0.5017 100.34
  0.75 0.7574 100.99
  1.0 0.9964 99.64
X'    100.54
± SD    ± 3.54
% RSD    3.52
% Error    1.57
Glimepiride 0.10 0.1072 107.20
  0.25 0.2487 99.48
  0.50 0.4925 98.50
  0.75 0.7440 99.20
  1.0 1.008 100.80
X'    101.04
± SD    ± 3.55
% RSD    3.51
% Error    1.57